SES
NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the competent authority)i | |||||||||
1. Identity of the issuer or the underlying issuer of existing
shares to which voting rights are attached
ii
:
SES S.A. |
|||||||||
2. Reason for the notification
(please tick the appropriate
box or boxes):
[X] An acquisition or disposal of voting rights [ ] An acquisition or disposal of financial instruments [ ] An event changing the breakdown of voting rights [ ] Other (please specify)iii : |
|||||||||
3. Details of person subject to the notification obligation iv : | |||||||||
Name:
The Capital Group Companies, Inc. (“CGC”) |
City and country of registered office (if applicable):
Los Angeles, California, U.S.A. |
||||||||
4. Full name of shareholder(s)
(if different from 3.)v
:
See section 8 |
|||||||||
5. Date on which the threshold was crossed or reached
vi
:
22 February 2018 |
|||||||||
6. Total positions of person(s) subject to the notification obligation: | |||||||||
% of voting rights attached to shares (total of 7.A) |
% of voting rights through financial instruments (total of 7.B.1 + 7.B.2) |
Total of both in % (7.A + 7.B) | Total number of voting rights of issuervii | ||||||
Resulting situation on the date on which threshold was crossed or reached | 4.96% | 0.00% | 4.96% | 575,186,400 | |||||
Position of previous notification (if applicable) | 5.00% | 0.00% | 5.00% |
7. Notified details of the resulting situation on the date on which the threshold was crossed or reached viii : |
|||||||||||||||||||||||||
A: Voting rights attached to shares | |||||||||||||||||||||||||
Class/type of
shares ISIN code (if possible) |
Number of voting rights ix | % of voting rights | |||||||||||||||||||||||
Direct
(Art 9 of Directive 2004/109/EC) |
Indirect
(Art 10 of Directive 2004/109/EC) |
Direct
(Art 9 of Directive 2004/109/EC) |
Indirect
(Art 10 of Directive 2004/109/EC) |
||||||||||||||||||||||
LU0088087324 | 28,553,382 | 4.96% | |||||||||||||||||||||||
SUBTOTAL A | 28,553,382 | 4.96% | |||||||||||||||||||||||
|
|||||||||||||||||||||||||
B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC | |||||||||||||||||||||||||
Type of financial instrument |
Expiration
date x |
Exercise/
Conversion Period xi |
Number of voting rights that may be acquired if the instrument is exercised/ converted. | % of voting rights | |||||||||||||||||||||
SUBTOTAL B.1 | |||||||||||||||||||||||||
|
|||||||||||||||||||||||||
B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC | |||||||||||||||||||||||||
Type of financial instrument |
Expiration
date x |
Exercise/
Conversion Period x i |
Physical or cash settlement xii | Number of voting rights | % of voting rights | ||||||||||||||||||||
SUBTOTAL B.2 |
8. Information in relation to the person subject to the
notification obligation
(please tick the applicable box):
[ ] Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer. xiii
[X] Full chain of controlled undertakings through
which the voting rights and/or the
|
|||||||
Name xv | % of voting rights if it equals or is higher than the notifiable threshold | % of voting rights through financial instruments if it equals or is higher than the notifiable threshold | Total of both if it equals or is higher than the notifiable threshold | ||||
The Capital Group Companies, Inc.
Holdings by CG Management Companies below: |
4.96% | 0.00% | 4.96% | ||||
Capital Research and Management Company1 | |||||||
Capital Guardian Trust Company2 | |||||||
Capital International, Inc.2 | |||||||
Capital International Limited2 | |||||||
Capital International Sárl2 | |||||||
1. Wholly Owned subsidiary of The Capital Group Companies, Inc.
2. Wholly owned indirect subsidiaries of Capital Research and Management Company |
|||||||
9. In case of proxy voting: [name of the proxy holder ] will cease to hold [% and number ] voting rights as of [date ] | |||||||
10. Additional information
xvi
:
The Capital Group Companies, Inc. (“CGC”) is the parent company of Capital Research and Management Company (“CRMC”). CRMC is a U.S.-based investment management company that manages the American Funds family of mutual funds. CRMC manages equity assets for various investment companies through three divisions, Capital Research Global Investors, Capital International Investors and Capital World Investors. CRMC in turn is the parent company of Capital Group International, Inc. (“CGII”), which in turn is the parent company of five investment management companies (“CGII management companies”): Capital Guardian Trust Company, Capital International, Inc., Capital International Limited, Capital International Sàrl and Capital International K.K. The CGII management companies primarily serve as investment managers to institutional clients. Neither CGC nor any of its affiliates own shares of the issuer for its own accounts. Rather, the shares reported are owned by funds and accounts under the discretionary investment management of one or more of the investment management companies described above. |
Done at Los Angeles, California, U.S.A. on 23 February 2018.
View source version on businesswire.com: http://www.businesswire.com/news/home/20180226005531/en/
Contact:
SES
Pierre Margue
Legal Services Corporate and Finance
Tel.
+352 710 725 276
Pierre.margue@ses.com
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NY-HCLTECH26.4.2024 22:07:31 CEST | Press release
HCLTech Reports FY24 Revenue of $13.3 Billion, up 5.4% YoY
KINAXIS-INC.26.4.2024 18:04:28 CEST | Press release
Kinaxis Positioned Highest on Ability to Execute in the Gartner® Magic Quadrant™ for Supply Chain Planning Solutions
VERTEX-PHARMA26.4.2024 17:44:28 CEST | Press release
Vertex Announces European Commission Approval for KALYDECO® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older
SUZANO-S.A.26.4.2024 17:23:27 CEST | Press release
Suzano 2023 annual report on Form 20-F
MA-TAKEDA-PHARMACEUTICAL26.4.2024 14:31:34 CEST | Press release
Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom